WaveBreak
Bart Henderson has an extensive background in the pharmaceutical and biotechnology industry, holding various leadership roles in different companies over the years. Currently, Bart serves as the Chief Executive Officer and President at WaveBreak and as the Co-Founder of FUSE Therapeutics. Their experience includes roles such as Operating Partner at Flagship Pioneering, CEO, President, and Co-Founder at Torque, and President and Founder at Rhythm Pharmaceuticals Inc. Bart also has a strong educational background with a BA from Amherst College and an MBA from The Tuck School of Business at Dartmouth.
WaveBreak
WaveBreak is a biopharmaceutical company focused on transforming drug discovery for neurodegenerative diseases, targeting the fleeting protein intermediates central to many disease pathways that are beyond the reach of conventional drug discovery approaches. WaveBreak has built a unique drug discovery platform to target the transient protein intermediates—the oligomers—in these disease pathways, to interrupt the molecular mechanisms that are the source of oligomer generation with small-molecule therapeutics. WaveBreak is focusing this platform first on some of the greatest unmet medical needs of our time: Parkinson’s disease, Lewy body dementia, Alzheimer’s disease, and ALS.